Dry Eye Disease(DED)

What is Dry Eye Disease?

DED is an abnormality caused by changes in the tear film and the ocular surface, which normally keeps the eye soft and comfortable by moisturizing the eye. Symptoms include overall dryness, burning, grittiness, and foreign body sensation. There are increasing numbers of patients who experience dry eye disease due to aging, increased computer and smart phone use, pollution, dry environment, refractive index surgery, and certain medications.

Currently developing a treatment for dry eye disease using Tβ4.
Expecting an effective treatment that improves the signs and symptoms of dry eye disease.

ReGenTree has contracted with Ora, Inc., a CRO and SMO company specializing in ophthalmological diseases in the US, to conduct clinical trials to develop the treatment for Dry Eye Disease. The clinical trial uses the CAE^SM (Controlled Adverse Environment) model to create a more uniform patient response with moderate to severe dry eye. The CAE^SM Model standardizes influential factors (e.g. relative humidity, temperature and visual tasking) that exacerbate dry eye disease resulting in reduced endpoint variability and improved likelihood of trial success. The CAE^SM model also allows for rapid data acquisition.
Completed a Phase IIb/III clinical trial(ARISE-1) of RGN-259 for the treatment of Dry Eye Disease in the US
Completed a 2nd Phase III clinical trial(ARISE-2) of RGN-259 for treatment of Dry Eye Disease in the US
Completed a 3rd Phase III clinical trial(ARISE-3) of RGN-259 for the treatment of Dry Eye Disease in the US
Planning a 4th Phase III clinical trial(ARISE-4) of RGN-259 for the treatment of Dry Eye Disease in the US

ReGenTree has exclusive rights for the development and commercialization of RGN-259 in Worldwide (other than China, Hong Kong, Taiwan).

Please contact HLB Therapeutics if you are interested in partnering (other than China, Hong Kong, Taiwan).